0 Items
Toll Free (US) - +1-866-598-1553
sales@precisionbusinessinsights.com
Latin America Gastric Cancer Treatment Market: Estimation, Dynamics, Regional Share, Trends, Competitor Analysis (2017-2021) and Forecast (2022-2028)

Latin America Gastric Cancer Treatment Market: Estimation, Dynamics, Regional Share, Trends, Competitor Analysis (2017-2021) and Forecast (2022-2028)

$ PRICE - $ 3,000.00 – $ 8,900.00

Latin America Gastric Cancer Treatment Market: By Treatment (Chemotherapy, Adjuvant Chemotherapy, Radiation Therapy, Surgery, Targeted Therapy), By Cancer Type (Laryngeal Cancer, Lip and Oral Cavity Cancer, Nasopharyngeal Cancer, Oropharyngeal Cancer, Salivary Gland Cancer, Others), By End User (Hospitals, Clinics, Ambulatory Surgical Centers, Specialized Cancer Treatment Centers) and Geography

Request Sample Request Methodology
Request Sample Read More
$ PRICE - $ 3,000.00 – $ 8,900.00
Clear selection
Clear
$ PRICE - $ 3,000.00 – $ 8,900.00
FacebookTwitterLinkedinEmail
SKU: N/A Categories: ,
Report

Description

Latin America Gastric Cancer Treatment Market size was valued at USD million in 2021 and is expected to reach a value of USD million by 2028, growing at a significant CAGR during the forecast period 2022 to 2028. The global market provides a detailed overview of the gastric cancer treatment market and that can be segmented by treatment, cancer type, and end user. By treatment, the gastric cancer treatment market has been segmented into chemotherapy, adjuvant chemotherapy, radiation therapy, surgery, and targeted therapy. The chemotherapy segment is likely to be the largest and fastest-growing segment in terms of treatment. Based on cancer type, the gastric cancer treatment market is segmented into laryngeal cancer, lip and oral cavity cancer, nasopharyngeal cancer, oropharyngeal cancer, salivary gland cancer, and others. Among these, the laryngeal cancer segment is expected to have the fastest-growing market during the forecast period 2022-2028. On the basis of end-users, the market is segregated into hospitals, clinics, ambulatory surgical centers, and specialized cancer treatment centers. The hospitals segment held a considerable market share during the forecast period.

Latin America Gastric Cancer Treatment Market

MARKET SUMMARY
-
x%
  • Study Period– 2022-2028
  • Base Year– 2021
  • CAGR– x%

Latin America Gastric Cancer Treatment Market

  • The report on latin america gastric cancer treatment market gives historical, current, and future market sizes (US$ Bn) on the basis of device type, application, end user and geography.
  • The latin america gastric cancer treatment market report gives comprehensive outlook across the region with special emphasis on key regions
Key Players
  • Abbott Laboratories, Inc.
  • AstraZeneca plc
  • Eli Lilly and Company
  • Hoffmann-La Roche Ltd
  • GlaxoSmithKline plc
Latin America Gastric Cancer Treatment Market Drivers

Some of the key factors fueling the market growth include quick regulatory agency approval of gastric cancer medications, the rapid development of sophisticated diagnostic equipment, increased public awareness of the signs and causes of gastric cancer, and introduction of novel therapies for metastatic stomach cancer.

Latin America Gastric Cancer Treatment Market

Latin America
Latin-America
North-America
North-America
Europe
Europe
Asia Pacific
Asia-Pacific
Middle East
Middle East
Key

Features of the Report

  • The gastric cancer treatment market report provides granular level information about the market size, regional market share, historic market (2017-2021) and forecast (2022-2028)
  • The gastric cancer treatment market report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The gastric cancer treatment market report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The gastric cancer treatment market report tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The gastric cancer treatment market report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
Latin America Gastric Cancer Treatment Market Segmentation

segmentation-block-image

By Treatment

    • Chemotherapy,
    • Adjuvant Chemotherapy,
    • Radiation Therapy,
    • Surgery,
    • Targeted Therapy
segmentation-block-image

By Cancer Type

    • Laryngeal Cancer,
    • Lip and Oral Cavity Cancer,
    • Nasopharyngeal Cancer,
    • Oropharyngeal Cancer,
    • Salivary Gland Cancer,
    • Others
segmentation-block-image

By End User

    • Hospitals,
    • Clinics,
    • Ambulatory Surgical Centers,
    • Specialized Cancer Treatment Centers
Location

GEOGRAPHY

Frequently Asked Questions

The latin america gastric cancer treatment market is projected to expand at a CAGR of x% during the forecast period.

The major players in the global gastric cancer treatment market are Abbott Laboratories, Inc., AstraZeneca plc, Eli Lilly and Company, Hoffmann-La Roche Ltd, GlaxoSmithKline plc, Amgen, Inc, Celgene corporation, Novartis AG, Jiangsu Hengrui Medicine Co., Ltd, TAIHO PHARMACEUTICAL CO., LTD, Celltrion Inc., Bristol-Myers Squibb Company, Bayer AG and Merck & Co., Inc.

Report

Table Of Content

1. Executive Summary
2. Latin America Gastric Cancer Treatment Market Introduction
2.1. Latin America Gastric Cancer Treatment Market – Taxonomy
2.2. Latin America Gastric Cancer Treatment Market –Definitions
2.2.1. By Treatment
2.2.2. By Cancer Type
2.2.3. By End User
2.2.4. By Country
3. Latin America Gastric Cancer Treatment Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Epidemiology Studies
3.6. Pipeline Analysis
3.7. Clinical Trails Analysis
3.8. Drug Approvals and Estimated Launch Years
3.9. Latin America Gastric Cancer Treatment Market Dynamic Factors – Impact Analysis
3.10. Latin America Gastric Cancer Treatment Market – Competition Landscape
4. Latin America Gastric Cancer Treatment Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028
4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Opportunity Analysis
5. Latin America Gastric Cancer Treatment Market, By Treatment, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.1. Chemotherapy
5.1.1. Programmed Cell Death Protein 1 (PD-1) Inhibitors
5.1.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.1.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.1.3. Market Opportunity Analysis
5.1.2. Human Epidermal Growth Factor Receptor (HER2) Antagonists
5.1.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.1.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.2.3. Market Opportunity Analysis
5.1.3. Vascular Endothelial Growth Factor Receptor (VEGFR) Antagonists
5.1.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.1.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.3.3. Market Opportunity Analysis
5.1.4. Others
5.1.4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.1.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.4.3. Market Opportunity Analysis
5.2. Adjuvant Chemotherapy
5.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.3. Market Opportunity Analysis
5.3. Radiation Therapy
5.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.3.3. Market Opportunity Analysis
5.4. Surgery
5.4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.4.3. Market Opportunity Analysis
5.5. Targeted Therapy
5.5.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.5.3. Market Opportunity Analysis
6. Latin America Gastric Cancer Treatment Market Forecast, By Cancer Type, 2017 – 2021 and Forecast, 2022 – 2028
6.1. Laryngeal Cancer
6.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.3. Market Opportunity Analysis
6.2. Lip and Oral Cavity Cancer
6.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.3. Market Opportunity Analysis
6.3. Nasopharyngeal Cancer
6.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.3.3. Market Opportunity Analysis
6.4. Oropharyngeal Cancer
6.4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.4.3. Market Opportunity Analysis
6.5. Salivary Gland Cancer
6.5.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
6.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.5.3. Market Opportunity Analysis
6.6. Others
6.6.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
6.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.6.3. Market Opportunity Analysis
7. Latin America Gastric Cancer Treatment Market Forecast, By Cancer Type, 2017 – 2021 and Forecast, 2022 – 2028
7.1. Hospitals
7.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.1.3. Market Opportunity Analysis
7.2. Clinics
7.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.2.3. Market Opportunity Analysis
7.3. Ambulatory Surgical Centers
7.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.3.3. Market Opportunity Analysis
7.4. Specialized Cancer Treatment Centers
7.4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.4.3. Market Opportunity Analysis
8. Latin America Gastric Cancer Treatment Market Forecast, By Country, 2017 – 2021 and Forecast, 2022 – 2028
8.1. Brazil
8.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.1.3. Market Opportunity Analysis
8.2. Mexico
8.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.2.3. Market Opportunity Analysis
8.3. Argentina
8.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.3.3. Market Opportunity Analysis
8.4. Rest of Latin America
8.4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.4.3. Market Opportunity Analysis
8.5. Latin America Gastric Cancer Treatment Market – Opportunity Analysis Index, By Treatment, End User and Country 2020 – 2026
9. Brazil Gastric Cancer Treatment Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
9.1. By Treatment Analysis 2017 – 2021 and Forecast, 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
9.1.1. Chemotherapy
9.1.1.1. Programmed Cell Death Protein 1 (PD-1) Inhibitors
9.1.1.2. Human Epidermal Growth Factor Receptor (HER2) Antagonists
9.1.1.3. Vascular Endothelial Growth Factor Receptor (VEGFR) Antagonists
9.1.1.4. Others
9.1.2. Adjuvant Chemotherapy
9.1.3. Radiation Therapy
9.1.4. Surgery
9.1.5. Targeted Therapy
9.2. By Cancer Type Analysis 2017 – 2021 and Forecast, 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
9.2.1. Laryngeal Cancer
9.2.2. Lip and Oral Cavity Cancer
9.2.3. Nasopharyngeal Cancer
9.2.4. Oropharyngeal Cancer
9.2.5. Salivary Gland Cancer
9.2.6. Others
9.3. By End User Analysis 2017 – 2021 and Forecast, 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
9.3.1. Hospitals
9.3.2. Clinics
9.3.3. Ambulatory Surgical Centers
9.3.4. Specialized Cancer Treatment Centers
9.4. Brazil Gastric Cancer Treatment Market – Opportunity Analysis Index, By Treatment, By Cancer and End User, 2020 – 2026
9.5. Brazil Gastric Cancer Treatment Market Dynamics – Opportunities
10. Mexico Gastric Cancer Treatment Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
10.1. By Treatment Analysis 2017 – 2021 and Forecast, 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.1.1. Chemotherapy
10.1.1.1. Programmed Cell Death Protein 1 (PD-1) Inhibitors
10.1.1.2. Human Epidermal Growth Factor Receptor (HER2) Antagonists
10.1.1.3. Vascular Endothelial Growth Factor Receptor (VEGFR) Antagonists
10.1.1.4. Others
10.1.2. Adjuvant Chemotherapy
10.1.3. Radiation Therapy
10.1.4. Surgery
10.1.5. Targeted Therapy
10.2. By Cancer Type Analysis 2017 – 2021 and Forecast, 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.2.1. Laryngeal Cancer
10.2.2. Lip and Oral Cavity Cancer
10.2.3. Nasopharyngeal Cancer
10.2.4. Oropharyngeal Cancer
10.2.5. Salivary Gland Cancer
10.2.6. Others
10.3. By End User Analysis 2015 – 2019 and Forecast 2020 – 2026 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.3.1. Hospitals
10.3.2. Clinics
10.3.3. Ambulatory Surgical Centers
10.4. Specialized Cancer Treatment CentersMexico Gastric Cancer Treatment Market – Opportunity Analysis Index, By Treatment, By Cancer Type and End User, 2022 – 2028
10.5. Mexico Gastric Cancer Treatment Market Dynamics – Opportunities
11. Argentina Gastric Cancer Treatment Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
11.1. By Treatment Analysis 2017 – 2021 and Forecast, 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.1.1. Chemotherapy
11.1.1.1. Programmed Cell Death Protein 1 (PD-1) Inhibitors
11.1.1.2. Human Epidermal Growth Factor Receptor (HER2) Antagonists
11.1.1.3. Vascular Endothelial Growth Factor Receptor (VEGFR) Antagonists
11.1.1.4. Others
11.1.2. Adjuvant Chemotherapy
11.1.3. Radiation Therapy
11.1.4. Surgery
11.1.5. Targeted Therapy
11.2. By Cancer Type Analysis 2017 – 2021 and Forecast, 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.2.1. Laryngeal Cancer
11.2.2. Lip and Oral Cavity Cancer
11.2.3. Nasopharyngeal Cancer
11.2.4. Oropharyngeal Cancer
11.2.5. Salivary Gland Cancer
11.2.6. Others
11.3. By End User Analysis 2017 – 2021 and Forecast, 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.3.1. Hospitals
11.3.2. Clinics
11.3.3. Ambulatory Surgical Centers
11.4. Argentina Countries Gastric Cancer Treatment Market – Opportunity Analysis Index, By Treatment, By Cancer Type and End User, 2020 – 2028
11.5. Argentina Gastric Cancer Treatment Market Dynamics – Opportunities
12. Rest of Latin America Gastric Cancer Treatment Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
12.1. By Treatment Analysis 2017 – 2021 and Forecast, 2022 – 2028  by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.1.1. Chemotherapy
12.1.1.1. Programmed Cell Death Protein 1 (PD-1) Inhibitors
12.1.1.2. Human Epidermal Growth Factor Receptor (HER2) Antagonists
12.1.1.3. Vascular Endothelial Growth Factor Receptor (VEGFR) Antagonists
12.1.1.4. Others
12.1.2. Adjuvant Chemotherapy
12.1.3. Radiation Therapy
12.1.4. Surgery
12.1.5. Targeted Therapy
12.2. By Cancer Type Analysis 2017 – 2021 and Forecast, 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.2.1. Laryngeal Cancer
12.2.2. Lip and Oral Cavity Cancer
12.2.3. Nasopharyngeal Cancer
12.2.4. Oropharyngeal Cancer
12.2.5. Salivary Gland Cancer
12.2.6. Others
12.3. By End User Analysis 2017 – 2021 and Forecast, 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.3.1. Hospitals
12.3.2. Clinics
12.3.3. Ambulatory Surgical Centers
12.4. Rest of Latin America Countries Gastric Cancer Treatment Market – Opportunity Analysis Index, By Treatment, By Cancer Type and End User, 2022 – 2028
12.5. Rest of Latin America Gastric Cancer Treatment Market Dynamics – Opportunities
13. Competition Landscape
13.1. Strategic Dashboard of Top Market Players
13.2. Company Profiles (Introduction, Financial Analysis, Product Type & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
13.2.1. Abbott Laboratories, Inc.
13.2.2. AstraZeneca plc
13.2.3. Eli Lilly and Company
13.2.4. Hoffmann-La Roche Ltd
13.2.5. GlaxoSmithKline plc
13.2.6. Amgen, Inc
13.2.7. Celgene corporation
13.2.8. Novartis AG
13.2.9. Jiangsu Hengrui Medicine Co., Ltd
13.2.10. TAIHO PHARMACEUTICAL CO., LTD
13.2.11. Celltrion Inc.
13.2.12. Bristol-Myers Squibb Company
13.2.13. Bayer AG
13.2.14. Merck & Co., Inc.
14. Research Methodology
15. Key Assumptions and Acronyms
Report

Company Profile

  • Abbott Laboratories, Inc.
  • AstraZeneca plc
  • Eli Lilly and Company
  • Hoffmann-La Roche Ltd
  • GlaxoSmithKline plc
  • Amgen, Inc
  • Celgene corporation
  • Novartis AG
  • Jiangsu Hengrui Medicine Co., Ltd
  • TAIHO PHARMACEUTICAL CO., LTD
  • Celltrion Inc.
  • Bristol-Myers Squibb Company
  • Bayer AG
  • Merck & Co., Inc.

Description

Latin America Gastric Cancer Treatment Market size was valued at USD million in 2021 and is expected to reach a value of USD million by 2028, growing at a significant CAGR during the forecast period 2022 to 2028. The global market provides a detailed overview of the gastric cancer treatment market and that can be segmented by treatment, cancer type, and end user. By treatment, the gastric cancer treatment market has been segmented into chemotherapy, adjuvant chemotherapy, radiation therapy, surgery, and targeted therapy. The chemotherapy segment is likely to be the largest and fastest-growing segment in terms of treatment. Based on cancer type, the gastric cancer treatment market is segmented into laryngeal cancer, lip and oral cavity cancer, nasopharyngeal cancer, oropharyngeal cancer, salivary gland cancer, and others. Among these, the laryngeal cancer segment is expected to have the fastest-growing market during the forecast period 2022-2028. On the basis of end-users, the market is segregated into hospitals, clinics, ambulatory surgical centers, and specialized cancer treatment centers. The hospitals segment held a considerable market share during the forecast period.

Reviews

There are no reviews yet.

Be the first to review “Latin America Gastric Cancer Treatment Market: Estimation, Dynamics, Regional Share, Trends, Competitor Analysis (2017-2021) and Forecast (2022-2028)”

Your email address will not be published. Required fields are marked *

ASIA PACIFIC OFFICE

Precision Business Insights, 5th Floor, Mohan’s Elite, Opp : Bharat Petroleum Pump, Khanamet Road, Hitech City, Hyderabad – 500084

EUROPE OFFICE

Precision Business Insights, Kemp House, 152 – 160 City Road, London EC1V 2NX

QUICKLINKS
RESEARCH AREAS
PRESS RELEASE
CONTACT US
+1-866-598-1553
EMAIL
sales@precisionbusinessinsights.com
FOLLOW US
QUICK LINKS+
RESEARCH AREAS+
PRESS RELEASE+
CONTACT US+
+1-866-598-1553
sales@precisionbusinessinsights.com
FOLLOW US AT+